Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Key Highlights
- ➤ART26.12 Phase 1 study showed no serious adverse events attributed to treatment
- ➤ART26.12 demonstrated predictable dose-proportional pharmacokinetics and wide estimated safety margin
- ➤Artelo plans to initiate a Phase 1 multiple ascending dose study in Q4 2026
- ➤ART26.12 reduced osteoarthritis pain comparably to naproxen with less stomach tissue damage
Expert Statements
Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences
“With the urgent need for effective alternatives to opioids, we believe ART26.12 represents a promising new approach to pain management as the first selective FABP5 inhibitor to advance into human clinical trials.”
Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences
“Presenting our growing body of data at the prestigious World Congress on Pain provides an important opportunity to engage directly with leading clinicians, researchers and key opinion leaders in the field, share our progress and explore the potential of this novel mechanism to address significant unmet needs in pain treatment.”
Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences
“ART26.12 has demonstrated promising analgesic activity across multiple nonclinical models of pain, including chemotherapy-induced peripheral neuropathy, while our Phase 1 results have provided encouraging safety and pharmacokinetic data in humans.”
Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences
“Together, these findings strengthen our confidence in the potential of FABP5 inhibition as a differentiated, non-opioid approach to pain management with a promising safety profile.”
Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences
“We have initiated steps to begin enrollment to our multiple ascending dose study, the next clinical development step planned for ART26.12.”
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals
Growing body of data supports ART26.12’s potential as a novel, non-opioid treatment for pain as the Company advances toward a multiple ascending dose (MAD) study
Get started
Create a free account to read the full story.